Maxim Kebenko

A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct, in patients with refractory solid tumors

Maxim Kebenko, Marie-Elisabeth Goebeler, M. Wolf et al. · OncoImmunology · 2018 · 170 citations · Full text

Immunology, Pharmacotherapy, Immunotherapeutics +19

A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating <i>FLT3</i> mutations

Walter Fiedler, Sabine Käyser, Maxim Kebenko et al. · British Journal of Haematology · 2015 · 104 citations · Full text

Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemia

Norbert Vey, Jacques Delaunay, Giovanni Martinelli et al. · Oncotarget · 2016 · 94 citations · Full text

T3-mediated expression of PGC-1α via a far upstream located thyroid hormone response element

Anne Wulf, Angelika Harneit, Meike Kröger et al. · Molecular and Cellular Endocrinology · 2008 · 92 citations · Full text

Transcriptional Regulation, Systems Biology, Endocrine Mechanism +8

ErbB2 signaling activates the Hedgehog pathway via PI3K–Akt in human esophageal adenocarcinoma: Identification of novel targets for concerted therapy concepts

Maxim Kebenko, Astrid Drenckhan, Stephanie J. Gros et al. · Cellular Signalling · 2014 · 47 citations

Cancer Research, Oncology, Esophageal Cancer +12